A few days after LEUKEMIA 360, one message continues to resonate clearly:
the momentum in leukemia research is not only scientific—it is collective.
From clinicians and academic researchers to biotech teams, industry partners, and patient organizations, the feedback has been remarkably consistent. The discussions were dense, the exchanges genuine, and the energy in the room unmistakable.
This is not anecdotal enthusiasm. It reflects a deeper shift in how leukemia innovation is now being conceived, structured, and accelerated.
From opening remarks to closing reflections, the programme articulated a coherent narrative: progress in leukemia depends on alignment across disciplines, institutions, and development stages.
Key highlights included:
Collaboration and acceleration, explored by Michael Zaiac, setting the strategic tone of the event
A focused T-ALL spotlight, with John DiPersio, Matthieu Simonin, and Guillaume Andrieu, addressing both biological complexity and therapeutic opportunity
Clinical research perspectives from Claire Biot and Norbert Vey, grounding innovation in real-world practice
A European perspective presented by Pascal Deschaseaux, situating leukemia research within a broader continental framework
Together, these sessions underscored a shared understanding: innovation cannot be fragmented if it is to be impactful.
A pivotal moment of the day was the presentation by Yves Collette on DS5, a collaborative initiative uniting five Carnot Institutes.
The project aims to reinforce Institut Carnot OPALE’s leukemia drug-screening platform, illustrating how structured cooperation can enhance early-stage discovery while maintaining translational relevance.
This type of initiative embodies a model increasingly recognized as essential: shared infrastructure, pooled expertise, and long-term strategic vision.
Innovation was not discussed in abstraction. It was demonstrated through:
Interactive R&D workshops and cooperative group discussions led by Hervé Dombret
Innovation pitches from emerging companies shaping the future of leukemia therapeutics:
Adreogen – Jean-Emmanuel Sarry
Orthos Therapeutics – Xavier Morelli
CARLA Biotherapeutics – Maxime Fredon
These exchanges highlighted a critical point: meaningful innovation emerges when academic insight, industrial execution, and clinical need converge early.
The day concluded with reflections from Arnaud Pigneux, drawing together the central themes of the event: cooperation, methodological rigor, and the responsibility to translate promise into patient benefit.
More than a conference, LEUKEMIA 360 functioned as a catalyst—confirming that the field is ready to move faster, provided it moves together.
As discussions continue beyond the event itself, one question remains open to all participants:
Which moment, session, or conversation reshaped your perspective?
? Save the date: LEUKEMIA 360 returns on 17 November 2026.
The ambition is clear: to make the next edition not just larger, but even more impactful.